Recognition that the commoner forms of cancer of the genital tract in women can be cured if treated at an early stage has focused interest in screening tests which can be applied on a wide scale. The current practice of examining cells in smears obtained from the vagina and uterus for evidence of cancerous change is of proved value (MacGregor'and Baird, 1963 ) but some simpler alternative would be welcome. Bonham and Gibbs (1962) and Bonham (1963) have reported encouraging results, using 6-phosphogluconate dehydrogenase (6-PGD) activity in vaginal fluid as a screening test for uterine cancer. We have independently carried out this biochemical assay in parallel with standard cytological and histological techniques and this report summarizes our findings in certain well-defined clinical groups.
Material and Methods
Most of 2,480 patients examined were attending gynaecological out-patient departments in London hospitals. Antenatal and post-natal patients were included. Some women were in-patients at the Royal Marsden Hospital with suspected uterine cancer.
Samples of vaginal fluid were collected and 6-PGD activity was determined, using the method of Bonham and Gibbs (1962) (Table III) . Samples were seldom taken during menstruation, since the presence of blood in a sample greatly increases the probability of a positive result.
The findings during and after pregnancy are summarized in Table IV . The relatively low incidence of false-positive results in the antenatal group is noteworthy. On the other hand, the enzyme test proved disappointing in detecting carcinoma-in-situ in the small number of cases reported. The diagnosis would have been missed in half the patients had 6-PGD activity been the only criterion used. In the present state of our understanding of carcinoma-in-situ it would not be considered tolerable to leave this group untreated.
It is, however, possible that the low enzyme activity reflects a very early stage in the natural history of the lesion. There is evidence in the histochemical work of Chayen and Bitensky (personal communication) that increased 6-PGD activity precedes the development of invasive characteristics in tumours of both skin and cervix. If this evidence can be strengthened it may prove possible to divide carcinomain-situ into two stages-one of " quiescence " and one of "incipient invasiveness." Failure to detect " quiescent " cases would then perhaps not be an absolute contraindication to the use of 6-PGD as a screening test.
We were unable to assess the enzyme test in antenatal or post-natal patients as no cases of cancer were encountered in this group.
It is clear that there are conditions much more common than genital cancer which are also associated with increased 6-PGD activity. Our data on these non-malignant conditions will be published in another paper. Here we note only that this greatly reduces the specificity of the enzyme assay as a screening test for genital cancer-a positive result has little diagnostic significance.
If we proposed to use a second screening test-for example, cytological examination of exfoliated cells-on all women exhibiting raised enzyme levels, a proportion of false-positive results in the enzyme test would be permissible; the extent to which such fallibility was acceptable would, however, depend on the cost and convenience of the enzyme procedure as compared with cytology. We estimate that where the incidence of false-positive results was higher than one in three no useful purpose would be served by applying the enzyme test first, and nothing would be gained by using 6-PGD assay in screening women over the age of 45, as the incidence of false-positive results in this group average 70%. In younger women the incidence of false-positive reactions, though still high, is not high enough to render the test valueless as a preliminary screening procedure, and in the antenatal group the situation may be even more favourable.
Summary
We have been able to confirm the findings of Bonham and Gibbs (1962) that 6-phosphogluconate dehydrogenase activity is consistently raised above normal levels in the vaginal fluid of patients with invasive carcinoma of the genital tract. There are, however, serious limitations to the use of the enzyme measurement as a screening test, as half the patients with carcinoma-in-situ do not exhibit increased activity of this enzyme, and there is a high incidence of raised enzyme levels in women without genital cancer.
